报价延迟最少15分钟:2025/09/04 02:29 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.29 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.55/-0.81
|
|
企业价值
470.38M
|
| 资产负债 |
|
每股账面净值
-1.77
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
70.84M
|
|
每股收益
1.09
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/04 02:29 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed byEurope, the Middle East and Africa (EMEA). |
